Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.
German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.
Finnish contract development and manufacturing organization (CDMO) Biovian, specializing in biopharmaceuticals, is investing more than €50 million to expand its manufacturing facility in Turku, Finland.
Indian CDMO Enzene Biosciences — a subsidiary of Alkem Laboratories — is to build a biopharmaceutical manufacturing plant on the Princeton West Innovation Campus in Hopewell, New Jersey, USA.
Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a restructuring of its Seattle operations.
